The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Open accessPublished version of a preprint
Abstract
Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from therapy with anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the identification of novel biomarkers for better personalized medicine. We produced large xenograft cohorts from 85 patient-derived, genetically characterized metastatic colorectal cancer samples (“xenopatients”) to discover novel determinants of therapeutic response and new oncoprotein targets. Serially passaged tumors retained the morphologic and genomic features of their original counterparts. A validation trial confirmed the robustness of this approach: xenopatients responded to the anti-EGFR antibody cetuximab with rates and extents analogous to those observed in the clinic and could be prospectively stratified as responders or nonresponders on the basis of several predictive biomarkers. Genotype–response correlations indicated HER2 amplification specifically in a subset of cetuximab-resistant, KRAS/NRAS/BRAF/PIK3CA wild-type cases. Importantly, HER2 amplification was also enriched in clinically nonresponsive KRAS wild-type patients. A proof-of-concept, multiarm study in HER2-amplified xenopatients revealed that the combined inhibition of HER2 and EGFR induced overt, long-lasting tumor regression. Our results suggest promising therapeutic opportunities in cetuximab-resistant patients with metastatic colorectal cancer, whose medical treatment in the chemorefractory setting remains an unmet clinical need. Significance: Direct transfer xenografts of tumor surgical specimens conserve the interindividual diversity and the genetic heterogeneity typical of the tumors of origin, combining the flexibility of preclinical analysis with the informative value of population-based studies. Our suite of patient-derived xenografts from metastatic colorectal carcinomas reliably mimicked disease response in humans, prospectively recapitulated biomarker-based case stratification, and identified HER2 as a predictor of resistance to anti-epidermal growth factor receptor antibodies and of response to combination therapies against HER2 and epidermal growth factor receptor in this tumor setting. Cancer Discovery; 1(6); 508–23. ©2011 AACR. Read the Commentary on this article by Ciardiello and Normanno, p. 472 This article is highlighted in the In This Issue feature, p. 457
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HER2 overexpression is a negative predictor associated with reduced efficacy of anti-EGFR therapy [31], and >36% of cetuximab-resistant mCRC with wild-type KRAS, NRAS, BRAF, and PI3K was found to display HER2 overexpression [32].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [32]
In the citing paper
“A series of studies have demonstrated that HER2 gene amplification or activating mutations can mediate resistance to anti-EGFR mAbs in CRC [27,178,179].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [27]
In the citing paper
“Preclinical studies have shown that the combination of HER2 and EGFR blockade can lead to CRC tumor regression [27,28,29].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [27]
In the citing paper
“Two independent studies have recently shown that HER2 amplification is a predictor of poor sensitivity to anti-EGFR antibodies [91, 92].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“In retrospective studies, patients with tumors featuring HER2 amplification or heregulin overexpression and treated with cetuximab or panitumumab experienced disease progression and shorter progression-free and overall survival compared with HER2 wild-type cases [91-93].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“only the dual targeting of HER2 and EGFR by combining a small-molecule inhibitor, such as the dual EGFR/HER2 inhibitor lapatinib, with a moAb, such as cetuximab or pertuzumab, induced overt and long-lasting tumor regressions in proof-of-concept trials in HER2-amplified xenopatients [91].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“Increased EGFR gene copy number could predict response among KRAS wild-type patients [53, 91, 111-113]”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“Strong preclinical evidence suggests that dual inhibition of ERBB2 is superior to monotherapy due to enhanced efficacy and reduced therapy resistance4648”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [46]
In the citing paper
“Bertotti et al. identified ERBB2 as a biomarker of resistance to anti-EGFR mAbs [113].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [113]
In the citing paper
“A total of 2–7% of unselected CRCs were found to have ERBB2/mutations, and this number was much higher in KRAS wild-type cases (13.6%) and in KRAS/NRAS/BRAF/PIK3CA quadruple wild-type cases (36% )[13, 113, 114].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [113]
In the citing paper
“Finally, using patient-derived colon cancer xenografts, Bertotti et al. identified HER2 gene amplification as a predictor of resistance to cetuximab among KRAS wild-type tumors (Bertotti et al., 2011).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Bertotti et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citationCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationUmar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Rüschoff, J., Fishel, R. A., Lindor, N. M., Burgart, L. J., Hamelin, R., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh034 · Cited by 3,181
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Self-citationCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Cited by
Sorted by citations
Items 701–800 of 944
Frequency of Her2-low in colorectal cancer and its relations with the tumor microenvironment
Lang‐Schwarz, C., Vieth, M. W., Dregelies, T., & Sterlacci, W. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154417 · Cited by 5
Xiu, Z., Yang, Q., Xie, F., Han, F., He, W., & Liao, W. (2024) · Journal of Tissue Engineering · doi:10.1177/20417314241255470 · Cited by 5
New frontiers in therapeutic resistance in cancer
Bianchi, A. S., Delorenzi, M., Gagnon-Kugler, T., Rousseau, C., & Batist, G. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.71 · Cited by 5
Floc’h, N., Guerriero, M. L., Ramos‐Montoya, A., Davies, B. R., Cairns, J., & Karp, N. A. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.036160 · Cited by 4
Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal
Tessier‐Cloutier, B., Cai, E., & Schaeffer, D. F. (2019) · Diagnostic Pathology · doi:10.1186/s13000-019-0843-z · Cited by 5
Stulpinas, A., Imbrasaitė, A., Krestnikova, N., & Kalvelytė, A. V. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.89395 · Cited by 7
Patient-Derived Organoids: Promises, Hurdles and Potential Clinical Applications
Hedayat, S., & Valeri, N. (2020) · Clinical Oncology · doi:10.1016/j.clon.2019.12.009 · Cited by 5
Kourié, H. R., Ibnshamsah, F., Zouein, J., Naim, N., Abbasi, S., Allahloubi, N. M. A., Al-Naqqash, M. A., Alolayan, A. A. M., Alshehri, A., Bitar, N., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0282 · Cited by 5
Preclinical models in oncological pharmacology: limits and advantages
Pagano, E., Bergamo, A., Carpi, S., Donnini, S., Villarosa, M. N. D., Serpe, L., & Lisi, L. (2021) · doi:10.36118/pharmadvances.2021.05 · Cited by 5
Mohamadzade, Z., Kolagar, T. H., Nemati, H., Javanmard, A., & Soltani, B. M. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30218 · Cited by 5
Richter‐Pechańska, P., Becker, M., Mayr, T., Hinzmann, B., Adams, H.-P., Klaman, I., Kretschmar, K.-H., Kretschmar, K., Stecker, K., Mantke, R., et al. (2013) · Journal of Cancer Therapy · doi:10.4236/jct.2013.42083 · Cited by 5
WITHDRAWN: Molecular classification of colorectal cancer: Current perspectives and controversies
Mohammed, A. A., Taani, H. E., EL-Khatib, H. M., Mirza, A. A., & El-Kashif, A. T. (2016) · Journal of the Egyptian National Cancer Institute · doi:10.1016/j.jnci.2015.11.004 · Cited by 5
RetractedImmunodeficient and Humanized Mice
Santagostino, S. F., Monette, S., Piersigilli, A., Godfrey, V., & HogenEsch, H. (2021) · Wiley eBooks · doi:10.1002/9781119624608.ch9 · Cited by 5
Abbas, N., Mourad, M., Smaily, H., Al Mahmasani, L., & Shamseddine, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073265 · Cited by 4
Oncogenic mutations of clinical significance in colorectal cancer
Lea, V., Lim, S. H.-S., & Lee, C. S. (2025) · Pathology · doi:10.1016/j.pathol.2025.05.001 · Cited by 4
Rationally designed treatment for metastatic colorectal cancer: Current drug development strategies
Spiliopoulou, P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i30.10288 · Cited by 4
Patient-derived xenografts as models for personalized medicine research in cancer
Carnero, A., Pérez, M., & Navas, L. E. (2016) · Cancer translational medicine · doi:10.4103/2395-3977.196913 · Cited by 4
Karimov, M., SCHERER, M., Franke, H., Ewe, A., & Aigner, A. M. (2022) · Biotechnology Journal · doi:10.1002/biot.202200415 · Cited by 4
Assessment of HER2 status of carcinomas of various localizations
Vtorushin, S. V., Krakhmal, N. V., Эдуардовна, З. Л., Кузнецова, О. А., Moskvina, L. V., & Франк, Г. А. (2023) · Russian Journal of Archive of Pathology · doi:10.17116/patol20238506131 · Cited by 5
Airoldi, M., Bartolini, M., Fazio, R., Farinatti, S., Daprà, V., Santoro, A., & Puccini, A. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01601-x · Cited by 5
The Role of HER2 in Cancer and Its Influence on the Tumor Microenvironment
Choi, S., Kim, M., & Kim, M. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1009458 · Cited by 4
Vecchione, L., Saridaki, Z., & Tejpar, S. (2011) · Current Colorectal Cancer Reports · doi:10.1007/s11888-011-0112-3 · Cited by 4
The role of mouse models in translational cancer research: present and future directions
Porru, M., & Leonetti, C. (2017) · Translational Medicine Reports · doi:10.4081/tmr.6598 · Cited by 4
Growth of Malignant Non-CNS Tumors Alters Brain Metabolome
KOVALCHUK, A. V., Nersisyan, L., Mandal, R., Wishart, D. S., Mancini, M., Sidransky, D., Kolb, B. E., & Kovalchuk, O. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00041 · Cited by 5
Yan, J., Wu, X., Yu, J., Ma, M., Yu, H., Xu, T., Tang, H., Xu, L., Dai, J., Si, L., et al. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000494 · Cited by 4
Preclinical Animal Models for Cancer Research and Drug Discovery
Dhumal, A., Bendale, K., & Chaudhari, P. R. (2019) · Springer eBooks · doi:10.1007/978-981-32-9816-3_9 · Cited by 4
Critical evaluation of an autologous peripheral blood mononuclear cell-based humanized cancer model
Janakiraman, H., Becker, S. A., Bradshaw, A., Rubinstein, M. P., & Camp, E. R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273076 · Cited by 4
Molecular Testing of Colorectal Cancer in the Modern Era
Vakiani, E. (2017) · Surgical pathology clinics · doi:10.1016/j.path.2017.07.013 · Cited by 5
State of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA
Heliebi, A. E., & Heitzer, E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814470-1.00005-8 · Cited by 4
Rihawi, K., Giampieri, R., Scartozzi, M., Pusceddu, V., Bonotto, M., Fasola, G., Cascinu, S., & Aprile, G. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1054479 · Cited by 4
Antoniotti, C., Ongaro, E., Falcone, A., & Cremolini, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082298 · Cited by 4
Siena, S., Chalabi, M., Goodwin, R. A., Osterlund, P. J., Penault-Llorca, F. M., Sartore-Bianchi, A., Starling, N., Stintzing, S., & Tabernero, J. M. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103097 · Cited by 3
Self-citationJian, C., Fu, H., Wu, W., Zhang, N., Liu, Z., Xia, Z., Luo, P., Zhang, H., & Cheng, Q. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02594-w · Cited by 4
Kawczak, P., & Bączek, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062387 · Cited by 4
Beyond RAS and BRAF: a target rich disease that is ripe for picking
Friedrich, T. J., Leong, S., & Lieu, C. H. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.06.11 · Cited by 3
Kim, S., Shin, D., Min, A., Kim, M., Na, D., Lee, H.-B., Ryu, H. S., Yang, Y., Woo, G.-U., Lee, K.-H., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02607-2 · Cited by 3
Jang, J. Y., Jeon, Y., Jeong, S. Y., Lim, S. H., Park, Y. S., Lim, H. Y., Lee, J. Y., & Kim, S. T. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-375 · Cited by 3
Metastatic colorectal cancer- third line therapy and beyond
Foo, T., Roy, A. C., Karapetis, C. S., Townsend, A. R., & Price, T. J. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2334784 · Cited by 3
Bianchi, A. S., & Siena, S. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_19 · Cited by 3
Self-citationPatient-Derived Xenografts as Cancer Models for Preclinical Drug Screening
Williams, J. A. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-55825-7_10 · Cited by 3
Hou, H., Liu, D., Zhang, C., Jiang, Y., Lu, G., Zhou, N., Yang, X., Zhang, X., Li, Z., Zhu, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21349 · Cited by 3
Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment.
Korphaisarn, K., Chou, C., Xia, W.-Y., Clarke, C. N., Katkhuda, R., Davis, J. S., Raghav, K. P. S., Liao, H.-W., Wu, J. Y., Menter, D. G., et al. (2017) · PubMed · Cited by 3
Rashid, M. U., Hussain, I., Jehanzeb, S., Ali, S., Jain, A. G., Kumar, R., Khetpal, N., & Ahmad, S. (2018) · Springer eBooks · doi:10.1007/978-981-13-1486-5_10 · Cited by 3
The Role of HER2 Testing in Advanced Colorectal Cancer
Mehta, R. J. (2018) · Current Colorectal Cancer Reports · doi:10.1007/s11888-018-0417-6 · Cited by 3
Value of Geriatric Assessment in Patients With Genitourinary Carcinoma
Zangl, Q. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3510.0620 · Cited by 3
Mohseni, N., Zarch, M. G., Afshar, S., & Hosseini, M. (2022) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-022-00873-5 · Cited by 3
Wang, M., Su, J., Lu, J., Yang, Z. X., Wang, J., Zhong, Y., Zeng, T., Shen, K., & Lin, S. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102078 · Cited by 3
Ferrarini, F., Zulato, E., Moro, M., Bianco, P. D., Borzi, C., Esposito, G., Zanin, T., Sozzi, G., & Indraccolo, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1070505 · Cited by 3
Liang, Y., Lin, H., Jiang, Z., Zhao, Q., Cui, R., & Li, S. (2024) · Discover Oncology · doi:10.1007/s12672-024-01440-z · Cited by 3
Development and Preclinical Evaluation of CDH17-Specific ImmunoPET Imaging in Colorectal Cancers
Pan, X., Wu, Q., Zhang, Y., Xu, D., Zhou, X., Li, L., Wang, C., Wei, W., An, S., Huang, G., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00525 · Cited by 3
Controversies in the treatment of RAS wild-type metastatic colorectal cancer
Vera, R., Salgado, M., Safont, M. J., Gallego-Plazas, J., González‐Flores, E., Élez, E., & Aranda, E. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02475-8 · Cited by 3
Using PDX for Biomarker Development
Struss, W. J., & Black, P. C. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-55825-7_9 · Cited by 2
Porru, M., Zizza, P., Panera, N., Alisi, A., Biroccio, A., & Leonetti, C. (2020) · Cancers · doi:10.3390/cancers12071830 · Cited by 3
Patient-Derived-Xenografts in Mice: A Preclinical Platform for Cancer ResearchPreprint
Cocco, E., & de Stanchina, E. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041381 · Cited by 3
Ma, X., Yu, Z., Cheng, L., & Wang, S. (2025) · International Journal of Pharmacology · doi:10.3923/ijp.2025.369.377 · Cited by 2
The application of experimental models for the drug discovery for digestive tumors
Zheng, L., Shuai, W., Liu, Y., Deng, Y., Bao, J., Hu, X., & Wang, G. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02558-6 · Cited by 2
Liu, M., Zhong, L., Dong, M., & Liu, T. (2026) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2026.2642646 · Cited by 2
Pastor, P. G., Gonzalez, N. S., Salvà, F., Ros, J., Baraibar, I., Rodríguez-Castells, M., de Torres, C. S., García, A., Alcaráz, A., Vaghi, C., et al. (2026) · Genes · doi:10.3390/genes17040460 · Cited by 2
Molecular profiling in colorectal cancer: current state of play and future directions
Deb, S., & Fox, S. B. (2014) · Colorectal Cancer · doi:10.2217/crc.13.82 · Cited by 2
Dong, X., Gout, P. W., Yi, L., Wang, Y., Xu, Y., & Yang, K. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-55825-7_11 · Cited by 2
Gordon, D., & Axelrod, D. E. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03942-y · Cited by 2
DNA Microarray Classification: Evolutionary Optimization of Neural Network Hyper-parameters
Barbiero, P., Bertotti, A., Ciravegna, G., Cirrincione, G., & Piccolo, E. (2019) · Smart innovation, systems and technologies · doi:10.1007/978-981-13-8950-4_28 · Cited by 2
Self-citationMaslov, A. A., Chalkhakhyan, L. K., Андреевич, М. С., Kaminskiy, G. V., & Арменовна, М. Э. (2022) · South Russian Journal of Cancer · doi:10.37748/2686-9039-2022-3-2-6 · Cited by 2
Targeting ERBB2 overcomes resistance to the anti-EGFR therapeutic antibody cetuximab
Wang, C., Li, T. X., Fu, W., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00031-6 · Cited by 2
Li, X., Huang, Y., Zheng, K., Yu, G., Wang, Q., Gu, L., Li, J., Wang, H., Zhang, W., Sun, Y., et al. (2023) · Biophysics Reports · doi:10.52601/bpr.2022.210048 · Cited by 2
Generation of Metastatic Cholangiocarcinoma Patient-Derived Xenograft Models
Yáñez-Bartolomé, M., Serra-Camprubí, Q., Arenas, E. J., Escorihuela, M., Castet, F., Fabregat-Franco, C., Querol, J., Arribas, J., Peiró, S., Macarulla, T. M., et al. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3858-3_11 · Cited by 2
Kim, K. Y., Lee, J. M., Lee, E. J., Jung, D., Goh, A.-R., Choi, M. C., Jung, S. G., Park, H., Hwang, S., Kang, H., et al. (2025) · Cells · doi:10.3390/cells14050325 · Cited by 2
Personalized therapy in metastatic colorectal cancer: biomarker-driven use of biologics
Sullo, F. G., Gallio, C., Matteucci, L., Bittoni, A., Muratore, M., Esposito, L., Ceredi, B., Gallo, G., Ulivi, P., Rapposelli, I. G., et al. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2556911 · Cited by 3
Meunier, K., Ferron, M., Calmel, C., Fléjou, J., Pocard, M. D., & Praz, F. (2017) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22472 · Cited by 2
A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab
Kasagi, Y., Oki, E., Ando, K., Kimura, Y., Ikegami, T., Saeki, H., Morita, M., Kusumoto, T., & Maehara, Y. (2013) · Case Reports in Oncology · doi:10.1159/000353781 · Cited by 2
New Targets and New Drug Development in Colorectal Cancer
Garrido-Castro, A. C., Saurí, T., & Macarulla, T. M. (2014) · Current Colorectal Cancer Reports · doi:10.1007/s11888-014-0235-4 · Cited by 2
New Adjuvant Trial Designs in Colon Cancer
Leal, A. D., Hubbard, J. M., Sargent, D. J., & Grothey, A. A. (2015) · Current Colorectal Cancer Reports · doi:10.1007/s11888-015-0297-y · Cited by 2
Surdez, D., & Daudigeos‐Dubus, E. (2016) · Revue d Oncologie Hématologie Pédiatrique · doi:10.1016/j.oncohp.2016.10.017 · Cited by 2
Patient-Derived Tumor Xenograft
Inghirami, G., Tinkey, P. T., de Stanchina, E., & Uthamanthil, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804010-2.00027-8 · Cited by 2
Fidelity and Stability of PDX Models
Li, G. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-55825-7_3 · Cited by 2
Resistance of Colorectal Tumors to Anti-EGFR Antibodies
Trusolino, L., & Leto, S. M. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_1 · Cited by 2
Self-citationUnderstanding Cancer Phenomenon at Gene Expression Level by using a Shallow Neural Network Chain
Barbiero, P., Bertotti, A., Ciravegna, G., Cirrincione, G., Piccolo, E., & Tonda, A. P. (2019) · Smart innovation, systems and technologies · doi:10.1007/978-981-13-8950-4_26 · Cited by 2
Self-citationERBB2 in anti-EGFR-resistant colorectal cancer: cancer stem cells come into play
Mouillet‐Richard, S. (2021) · Gut · doi:10.1136/gutjnl-2020-323924 · Cited by 2
Supervised Gene Identification in Colorectal Cancer
Barbiero, P., Bertotti, A., Ciravegna, G., Cirrincione, G., Pasero, E. G. A., & Piccolo, E. (2018) · Smart innovation, systems and technologies · doi:10.1007/978-3-319-95095-2_23 · Cited by 2
Self-citationBrown, L. C., Fisher, D. J., Adams, R., Seligmann, J. F., Seymour, M., Kaplan, R. S., Richman, S. D., Quirke, P., Butler, R., Roberts, H. C., et al. (2022) · Efficacy and Mechanism Evaluation · doi:10.3310/htnb6908 · Cited by 2
Lukman, K., Reza, A. T., Diposarosa, R., Rudiman, R., Sribudiani, Y., Bashari, M. H., Primastari, E., & Nugraha, P. (2023) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2023.24.4.1373 · Cited by 2
Guan, J.-L., Liu, J., Wáng, Q., Cong, Y., Chen, Y., Huang, K., Huang, M., & Huang, L. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i9.1065 · Cited by 2
Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer
Chen, Z., Chen, J., Gao, Y., & Quan, M. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1944108 · Cited by 2
Patient-Derived Xenografts From Lung Cancer and Their Potential Applications
Wang, L., Zhang, R., & Fang, B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804010-2.00020-5 · Cited by 1
Landscape of Current Targeted Therapies for Advanced Colorectal Cancer
Pissarra, A. J., Abreu, C., Mansinho, A., Costa, A. L., Dâmaso, S., Lobo-Martins, S., Martins, M., & Costa, L. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.93978 · Cited by 1
Molecular Oncology in Management of Colorectal Cancer
Vemala, R. N. G., Katti, S. V., Sirohi, B., Manikandan, D., & Nandakumar, G. (2021) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-021-01289-6 · Cited by 2
Chen, Z., & Shen, L. (2017) · Oncology and Translational Medicine · doi:10.1007/s10330-016-0187-7 · Cited by 1
Ueda, S., Tanaka, T., Hirosuna, K., Miyamoto, S., Murakami, H., Nishie, R., Tsuchihashi, H., Toji, A., Morita, N., Hashida, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031486 · Cited by 1
Developing New Immunotherapy Approaches for Colorectal Cancer
Kelly, G., Nowlan, B., Tria, S. M., Nikkhoo, A., Bond, C., & Whitehall, V. (2025) · Cancers · doi:10.3390/cancers17243929 · Cited by 1
Shi, Y., Wang, X., Xi, X., Wang, M., Guo, J. H., Zhang, X., Chen, D., & Yang, W. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261445706 · Cited by 1
Leto, S. M., Sassi, F. P., Zanella, E. R., Vurchio, V., Cottino, F., Ferri, M., Damico, A., Grassi, E., Bertotti, A., & Trusolino, L. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08900-0 · Cited by 1
Self-citationWang, X., Xiao, J., Yang, Y., & Li, T. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s573763 · Cited by 1
Zhang, K., & Wang, H. (2015) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2015.10.08 · Cited by 1
Animal Models to Test Adjuvant Treatment: An Experimental Model of Colon Cancer
Becherirat, S., Valamanesh, F., Eveno, C., Sedbon, J., André, T., & Pocard, M. D. (2013) · Current Colorectal Cancer Reports · doi:10.1007/s11888-013-0180-7 · Cited by 1
Optimization of Anti-EGFR Treatment of Advanced Colorectal Cancer
Vecchione, L. (2014) · Current Colorectal Cancer Reports · doi:10.1007/s11888-014-0232-7 · Cited by 1
Mechanisms of acquired resistance to anti-EGF receptor treatment in colorectal cancer
Montagut, C. O., & Albanell, J. (2012) · Colorectal Cancer · doi:10.2217/crc.12.62 · Cited by 1
Bianchini, G., & Gianni, L. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs636 · Cited by 1
Napolitano, T. T. S. (2014) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.s10-001
Organoid Culture: Applications in Development and Cancer
Cañadas, I., & Barbie, D. A. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-45397-2_3 · Cited by 1
Patient-Derived Xenografts in Oncology
Adeegbe, D. O., & Liu, Y. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-45397-2_2 · Cited by 1
Metadata
- Authors
- Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., Ribero, D., Russolillo, N., Muratore, A., Massucco, P., Pisacane, A., Molinaro, L., Valtorta, E., Sartore-Bianchi, A., Risio, M., Capussotti, L., Gambacorta, M., Siena, S., Medico, E., Sapino, A., Marsoni, S., Comoglio, P. M., Bardelli, A., & Trusolino, L.
- Affiliations
- IFOM (IT)
- Authors' Affiliations: 1Laboratory of Molecular Pharmacology, 2Laboratory of Oncogenomics, 3Laboratory of Systems Biology, 4Laboratory of Molecular Genetics, 5Division of Surgical Oncology, 6Unit of Pathology, 7Clinical Coordination Unit, and 8Molecular Clinical Oncology, Institute for Cancer Research and Treatment, Torino; Departments of 9Oncological Sciences and 10Biomedical Sciences and Human Oncology, University of Torino Medical School, Torino; 11Department of Surgery, Mauriziano Umberto I Hospital, Torino; 12FIRC Institute of Molecular Oncology, Milano; 13Division of Pathology, 14Falck Division of Medical Oncology, Ospedale Niguarda Ca' Granda, Milano; and 15Southern Europe New Drug Organization Foundation, Milano, Italy
- ORCID
- Venue
- Cancer Discovery
- Published
- 2011-11-01
- Volume
- 1
- Issue
- 6
- Pages
- 508-523
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W1987443121
- Cited by
- 939
- References
- 56
- Citations by year
- 2026: 24 · 2025: 42 · 2024: 46 · 2023: 79 · 2022: 72 · 2021: 74 · 2020: 71 · 2019: 86 · 2018: 86 · 2017: 90 · 2016: 71 · 2015: 62 · 2014: 60 · 2013: 48 · 2012: 23
- FWCI
- 21.44
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Associazione Italiana per la Ricerca sul Cancro
- Regione Piemonte
- Genentech
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- patient-derived xenografts, metastatic colorectal cancer, cetuximab resistance, HER2 amplification, anti-EGFR therapy, predictive biomarkers, combination therapy, KRAS wild-type, BRAF wild-type, treatment resistance, tumor heterogeneity
- MeSH terms
- Cetuximab, Aged, Aged, 80 and over, Animals, Antibodies, Monoclonal, Female, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Middle Aged, Prospective Studies, Biomarkers, Tumor, Colorectal Neoplasms, ras Proteins, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Mice, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
